Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy
September 14, 2017 08:00 ET
|
Phrixus Pharmaceuticals, Inc.
ANN ARBOR, Mich., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Phrixus Pharmaceuticals, Inc. (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy (DMD) and heart failure, today...